automated auditory brainstem response (aabr test) (Genomics England)
90
Structured Review
Genomics England
automated auditory brainstem response (aabr test)
Automated Auditory Brainstem Response (Aabr Test), supplied by Genomics England, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/automated+auditory+brainstem+response+(aabr+test)/automated+auditory+brainstem+response++aabr+test+/med_rxiv__2024__09__03__24312979-198-164-172
Average 90 stars, based on 1 article reviews
Automated Auditory Brainstem Response (Aabr Test), supplied by Genomics England, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/automated+auditory+brainstem+response+(aabr+test)/automated+auditory+brainstem+response++aabr+test+/med_rxiv__2024__09__03__24312979-198-164-172
Average 90 stars, based on 1 article reviews
automated auditory brainstem response (aabr test) - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Transplantation Assay:Article Title: Evaluating whole genome sequencing for rare diseases in newborn screening: evidence synthesis from a series of systematic reviews Article Snippet: .. These scenarios were primarily driven by the nature of the intervention(s) that could be introduced on detection of the condition, i.e.: widely available and relatively low-cost treatment that carries a low risk of harm (e.g. adverse effects) for the patient and wider family, e.g. vitamin therapy intervention centred around long-term surveillance to allow earlier detection of the clinical manifestation of the condition with the associated anxiety and costs both in terms of resource use and time required to attend appointments, e.g. regular outpatient appointments to assess biochemical or developmental changes ongoing long-term high-cost treatment, potentially with more significant side-effects and requiring hospital visits and long-term monitoring, e.g. high cost or new drugs with unpleasant or unknown side effects potentially curative interventions carrying high short-term risks and costs to NHS but long-term lower impact on both NHS, patients and their families, e.g. stem cell transplantation where existing screening and treatment pathways exist such that the impact of WGS would be incremental, e.g. hearing screening using Automated Auditory Brainstem Response (AABR test) and |